Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update

HAYWARD, Calif.--(BUSINESS WIRE)--Feb 21, 2024--

Related Keywords

California ,United States ,Johanna Mercier ,Terry Rosen ,Holli Kolkey ,Development Rd Expenses ,Twitter ,Corporate Communications ,Arcus Biosciences Inc ,Exchange Commission On ,Company Annual Report On Form ,Exchange Commission ,Chief Commercial Officer ,Domvanalimab Zimberelimab Milestones ,Safety Data ,Overall Survival ,Synthetic Control Arm ,Fourth Quarter ,Full Year ,Cash Equivalents ,Marketable Securities ,Call Information ,Access Code ,Arcus Biosciences ,Announced Clinical Studies ,Arcus Bioscience ,Private Securities Litigation Reform Act ,Annual Report ,Investor Inquiries ,Investor Relations ,Business Wire ,